Zealand Pharma

Develop and execute US market access strategies for rare disease and obesity portfolios, including payer engagement, value proposition, and innovative access models. | Requires 10+ years of US Market Access experience in biotech/pharma, with proven success in product launch strategies, payer ecosystem knowledge, and cross-functional leadership. | Does it excite you to work with Market Access? and do you have experience with Market Access Strategy and Execution? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague. Your new position Zealand Pharma is seeking a dynamic and experienced leader to serve as the Senior Director, Market Access Strategy and Execution. This role is critical in shaping and executing the company’s access strategy for upcoming launches in rare diseases and obesity. The ideal candidate will have deep knowledge of the US payer. The role requires collaboration across internal teams and external partners to ensure patient access, affordability, and commercial success. Key Responsibilities: Strategic Leadership: Develop and lead the US market access strategy for Zealand Pharma’s rare disease portfolio, ensuring alignment across pricing, reimbursement, distribution, patient support, and affordability programs. Lead access strategy and execution for obesity therapy in partnership with a commercialization partner, balancing independence with joint commercialization needs. Value Proposition & Evidence Strategy: Define the value proposition for different payer and stakeholder segments. Collaborate with Medical Affairs, HEOR, and Commercial teams to identify evidence needs, develop economic models, and shape compelling, payer-relevant scientific messaging. Payer Engagement & Segmentation: Drive payer segmentation to identify and prioritize key archetypes, including commercial plans, PBMs, Medicare, and Medicaid stakeholders. Develop and execute engagement strategies to influence access, reimbursement, and pricing outcomes. Pricing & Contracting: Contribute to pricing and contracting strategies, including WAC recommendations, discount modeling, and forecasting, in collaboration with Finance and Brand leadership. Monitor evolving payer market dynamics and propose innovative solutions to secure access. Tools, Resources, and Execution: Oversee the development of payer-facing resources, pull-through tools, and affordability initiatives. Lead vendor and consultant partnerships supporting access landscape assessments and tactical execution. Cross-Functional Integration: Ensure integration of access strategy into launch planning, patient journey design, and sales force training. Represent market access in internal planning forums and external alliance management settings. Innovative Access Models: Explore and implement innovative access and contracting approaches, including value-based agreements and novel payer collaborations to improve patient access. Your profile Experience: 10+ years of US Market Access experience within biotech/pharma, a national payer, or a pharmacy benefit manager (PBM). Successful track record of leading product launch strategies including pricing, reimbursement, and formulary access. Experience with national payer/PBM formulary strategy development and implementation. Expertise: Deep understanding of US payer and PBM ecosystems, including retail and specialty pharmacy dynamics, rebate structures, and access barriers. Strong grasp of employer and health plan segmentation and the incentive structures that influence formulary decision-making. Skills: Proven ability to lead cross-functional teams and work effectively with alliance partners in co-commercialization environments. Exceptional communication, strategic thinking, and presentation skills with the ability to influence executive-level stakeholders. Let’s bond and be bold We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let’s bond and be bold Interested in bonding with us? Then please apply no later than February 20th, 2026, or as soon as possible. The applications will be reviewed as they come in. While a cover letter is not required, please include a few sentences in your CV explaining your motivation for applying. We are committed to an inclusive recruitment process and welcome applications from all job applicants. The anticipated base pay range for this position is : $ 245,000 - $ 300,000 About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a team in the U.S. For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com. Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co-development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.